Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib vs placebo in radioiodine-refractory differentiated thyroid cancer (China)
CTR20140287Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vandetanib in thyroid cancer, sponsored by AstraZeneca. Started Apr 2014; status: active.
02
Drugs
vandetanib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on CTR20140287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140287.